Advertisement

Topics

Stem Cell Transplant From Matched Unrelated or Partially Matched Related Donors

2014-08-27 03:50:15 | BioPortfolio

Summary

To evaluate the use of unrelated donors for hematopoietic cell transplantation in the treatment of hematologic and lymphoid malignancies.

Description

Stem Cell Transplantation from Matched Unrelated or Partially Matched Related Donors Using a Preparatory Regimen Consisting of Fractionated Total Body Irradiation (FTBI) and Cyclophosphamide (CY). To administer high dose radio-chemotherapy followed by stem cell transplantation from a matched unrelated donor or a partially matched related donor.

Study Design

Allocation: Non-Randomized, Control: Uncontrolled, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Blood Cancer

Intervention

ablative allogeneic hematopoietic cell transplantation

Location

Stanford University School of Medicine
Stanford
California
United States
94305

Status

Active, not recruiting

Source

Stanford University

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:50:15-0400

Clinical Trials [6691 Associated Clinical Trials listed on BioPortfolio]

Allogeneic Hematopoietic Cell Transplantation Using TLI/ATG for Older Patients With Hematologic Malignancies

To measure how frequently and to what degree a complication of transplant cell acute graft versus host disease (GV/HD) occurs.

Study of Factors Involved in the Regulation of Immune Responses After Allogeneic Hematopoietic Stem Cell Transplantation

The study concerns donors and patients receiving allogeneic stem cell haematopoietic transplantation. The aim of the study is to analyse HSC graft content in immune effector T (naive, memo...

Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Lymphoma

This research study is assessing the feasibility of reduced intensity allogeneic hematopoietic stem cell transplantation (HSCT) as a possible treatment for relapsed / refractory non-Hodgki...

Study of Opebacan in Patients Undergoing Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

The objectives of this study are as follows: To demonstrate the safety of escalating doses of opebacan in subjects undergoing myeloablative allogeneic Hematopoietic Stem Cell Transplantat...

Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies

The purpose of this study is to determine the tolerability and efficacy in treating patients aged 51-60 with acute leukemia and in treating myelodysplastic syndromes (MDS) or myeloprolifer...

PubMed Articles [33735 Associated PubMed Articles listed on BioPortfolio]

Secondary acute myeloid leukemia and the role of allogeneic stem cell transplantation in a population-based setting.

Secondary AML (s-AML), including AML with an antecedent hematological disorder (AHD-AML) and therapy-related AML (t-AML), constitutes a large proportion of AML patients and is considered to confer a d...

OUTCOMES OF REDUCED INTENSITY CONDITIONING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION PERFORMED IN THE INPATIENT VERSUS OUTPATIENT SETTING.

Allogeneic hematopoietic cell transplantation (allo-HCT) with reduced intensity conditioning (RIC) is commonly performed as an inpatient procedure. The feasibility and outcomes of RIC allo-HCT in the ...

Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.

While use of geriatric assessment in the allogeneic hematopoietic cell transplantation setting has been reported, few studies have evaluated the impact of patient reported function on autologous trans...

OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS OVER 69 YEARS OF AGE WITH ACUTE MYELOID LEUKEMIA: ON BEHALF OF THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT.

Reduced intensity conditioning (RIC) enables allogeneic hematopoietic stem cell transplantation (HSCT) in older patients with acute myeloid leukemia (AML). Between 2004 and 2014, 713 patients ≥70 ye...

Increased Health Care Utilization and Costs during Allogeneic Hematopoietic Cell Transplant for Acute Leukemia and Myelodysplastic syndromes in Adolescents and Young Adults Compared to Children: A Multicenter Study.

Allogeneic hematopoietic cell transplant (HCT) is a curative option for patients with acute leukemia and myelodysplastic syndromes (MDS), but is associated with significant cost. When compared to chil...

Medical and Biotech [MESH] Definitions

Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.

The release of stem cells from the bone marrow into the peripheral blood circulation for the purpose of leukapheresis, prior to stem cell transplantation. Hematopoietic growth factors or chemotherapeutic agents often are used to stimulate the mobilization.

Transplantation of STEM CELLS collected from the fetal blood remaining in the UMBILICAL CORD and the PLACENTA after delivery. Included are the HEMATOPOIETIC STEM CELLS.

Transplantation of stem cells collected from the peripheral blood. It is a less invasive alternative to direct marrow harvesting of hematopoietic stem cells. Enrichment of stem cells in peripheral blood can be achieved by inducing mobilization of stem cells from the BONE MARROW.

The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.

More From BioPortfolio on "Stem Cell Transplant From Matched Unrelated or Partially Matched Related Donors"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Transplantation
Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Searches Linking to this Trial